15,000-woman waitlist suggests demand for precision health is accelerating, and that women are ready to move beyond medical guesswork.
When a healthcare startup launches with 15,000 women already waiting to sign up, it’s worth asking why.
The answer isn’t simply that AI is having another moment. It’s that many women have spent years moving between appointments, normal test results and lingering symptoms, often leaving without clear answers. That experience has become so common that it has reshaped expectations around healthcare itself.
Xella Health is betting that women are no longer willing to accept uncertainty as the default. The San Francisco-based startup has officially launched an AI-powered precision health platform designed specifically for women’s biology [1]. The company combines advanced laboratory testing with personal health information to assess the likelihood of more than 130 female-specific conditions, including endometriosis, Hashimoto’s disease, perimenopause and polyendocrine metabolic ovarian syndrome (PMOS), formerly known as PCOS.
Backed by $3.7 million in pre-seed funding, Xella’s early traction reflects growing demand for healthcare that explains why symptoms are happening, not simply how to manage them. For the longevity industry, preventing disease starts long before treatment; it starts with understanding the body well enough to recognize problems before they become harder to reverse.
Most diagnostic tests work like checking one warning light on a dashboard. They can tell you if something specific is wrong, but they rarely explain how multiple systems are interacting. Xella is trying to change that. Instead of looking at hormones alone or relying on genetics in isolation, the platform combines several layers of biological information – including genes, proteins, hormones, medical history, lifestyle and reported symptoms – to build a broader picture of health. Like assembling a jigsaw puzzle, one piece rarely reveals the full image, but enough connected pieces begin to show patterns that would otherwise remain invisible.
The company’s AI analyzes those patterns to estimate a woman’s likelihood of developing or already living with more than 130 conditions. Members then receive a personalized health report alongside a consultation with a telehealth physician, who can recommend further testing, treatment or referrals to specialists. The ambition is to give them a more complete map before decisions are made.
From Mammoth Biosciences to precision women’s health
Xella’s founders, Kelly Lacob, Adriana Dantas and Dr Jesus Ching, didn’t arrive from the traditional digital health world. The idea for the company emerged while the trio worked together at Mammoth Biosciences, a company known for developing next-generation molecular diagnostics built on CRISPR research [2].
Rather than treating diagnostics as isolated lab results, Xella approaches biology as an interconnected system. Its proprietary “dry lab”uses AI to organize enormous amounts of biological information into patterns that clinicians can actually use. The technology does not edit genes or perform gene therapy; instead, it applies the same data-driven mindset that has transformed modern molecular diagnostics – looking across multiple biological signals instead of searching for a single culprit.
In many ways, it’s less about finding one smoking gun than reading an entire weather forecast.
More than a new name for PCOS?
One subtle but notable detail in Xella’s launch is its use of the term polyendocrine metabolic ovarian syndrome (PMOS) rather than the more familiar PCOS.
While PCOS remains the widely recognized clinical diagnosis today, some researchers have argued that the traditional name places too much emphasis on ovarian cysts while overlooking the condition’s broader hormonal and metabolic effects.
By adopting PMOS terminology, Xella appears to be aligning with a growing conversation that views the condition as a complex metabolic disorder rather than solely a reproductive one. Names influence how diseases are understood, not only by patients, but also by clinicians, researchers and investors. Reframing the condition could ultimately encourage earlier intervention, broader screening and more holistic treatment strategies, although the wider medical community has yet to formally adopt the new terminology.
Turning data into evidence
For many women, delayed diagnosis is the expectation. Heart disease, autoimmune disorders and conditions such as endometriosis have long exposed the limitations of healthcare systems that were historically built around male-centered research. Endometriosis alone can take seven to ten years to diagnose, leaving patients to navigate chronic pain and unanswered questions during some of the most important years of their lives.
Kelly Lacob, the CEO and co-founder of Xella, said that women have been trapped in a diagnostic dark age where they routinely face systemic dismissal of debilitating symptoms such as severe period pain, bloating, gastrointestinal issues, exhaustion, and brain fog.
She explained that this ongoing neglect by the healthcare system causes women to wait an average of four years longer than men to be diagnosed with the same conditions. Moreover, Lacob highlighted that for specific health issues like endometriosis, women experience an accurate diagnosis delay of seven to ten years.
“Stalling necessary care and treatment results in prolonged suffering with chronic pain, heightened infertility risks, and declining mental health. Xella is here to replace the systemic medical gaslighting women have endured for generations,” she added. “We are handing women the evidence and information they need to advocate for themselves and secure faster, accurate diagnoses before early-stage conditions spiral.”
The emphasis on evidence also extends to how the platform follows users over time, rather than relying on a single snapshot.
Adriana Dantas, the co-founder and Chief Operating Officer, explained that women’s health data had historically been treated in isolated silos, noting that while individual tests like hormone evaluations or ultrasounds were conducted, no one was connecting the dots across the entire biology.
“By tracking unique biological patterns longitudinally across cycles and life stages, we aren’t just providing data, but a clear path forward,” Dantas said.
Longevity begins with being believed
The longevity movement often focuses on extending healthy years of life, but healthy aging depends on something more fundamental: knowing what’s happening inside the body early enough to do something about it.
Xella’s launch is notable because it reflects a broader change in expectations. Increasingly, patients are asking for healthcare that is predictive rather than reactive, personalized rather than generalized and built around their own biology rather than population averages.
That brings us back to the 15,000 women who joined the waitlist before the platform officially launched. Whether every promise lives up to expectations will ultimately depend on clinical outcomes. However, the waitlist itself already says something important: women are growing less willing to accept years of uncertainty as the cost of care, and that in the longevity era, better diagnostics may be just as valuable as better treatments.
[1] https://insider.fitt.co/xella-health-decodes-female-biology-launches-diagnostics-platform/
[2] https://www.biospace.com/press-releases/xella-health-launches-to-uniquely-detect-and-treat-130-often-misdiagnosed-womens-health-conditions
